

Abstract

The present invention relates to novel marker sequences that are differentially expressed in cancer cells or tissue of a subject with cancerous conditions. The present invention also relates to assays for diagnosis, prognosis, staging, monitoring, therapeutic
5 treatment, and marker sequence related agents including probes, primers, antibodies, and therapeutic compositions.